Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -1% Improvement Relative Risk Ventilation -18% Death/intubation -2% Discharge -2% Recovery Collaborative Group et al. NCT04381936 RECOVERY Colchicine RCT LATE Is late treatment with colchicine beneficial for COVID-19? RCT 11,340 patients in the United Kingdom Higher ventilation with colchicine (not stat. sig., p=0.06) Recovery Collaborative Group, The Lancet Respira.., doi:10.1016/S2213-2600(21)00435-5 Favors colchicine Favors control
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Recovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (date from earlier preprint), RECOVERY, NCT04381936 (history)
Recovery Collaborative Group, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label,.., , The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (date from earlier preprint), RECOVERY, NCT04381936
May 2021   Source   PDF  
  All Studies   Meta
RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none"). ISRCTN 50189673.
risk of death, 1.0% higher, RR 1.01, p = 0.77, treatment 1,173 of 5,610 (20.9%), control 1,190 of 5,730 (20.8%).
risk of mechanical ventilation, 18.0% higher, RR 1.18, p = 0.06, treatment 259 of 3,815 (6.8%), control 228 of 3,962 (5.8%).
risk of death/intubation, 2.0% higher, RR 1.02, p = 0.47, treatment 1,344 of 5,342 (25.2%), control 1,343 of 5,469 (24.6%).
risk of no hospital discharge, 2.0% higher, RR 1.02, p = 0.44, treatment 1,709 of 5,610 (30.5%), control 1,698 of 5,730 (29.6%), inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Recovery Collaborative Group et al., 18 May 2021, Randomized Controlled Trial, United Kingdom, peer-reviewed, 35 authors, average treatment delay 9.0 days, dosage 1.5mg day 1, 1mg days 2-10, dose for days 2-10 halved for certain patients, trial NCT04381936 (history) (RECOVERY).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Articles Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group* Summary Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19. Methods In this streamlined, randomised, controlled, open-label trial, underway at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Patients were eligible for inclusion in the study if they were admitted to hospital with clinically suspected or laboratory confirmed SARS-CoV-2 infection and had no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Eligible and consenting adults were randomly assigned (1:1) to receive either usual standard of care alone (usual care group) or usual standard of care plus colchicine (colchicine group) using web-based simple (unstratified) randomisation with allocation concealment. Participants received colchicine 1 mg after randomisation followed by 500 µg 12 h later and then 500 µg twice a day by mouth or nasogastric tube for 10 days in total or until discharge. Dose frequency was halved for patients receiving a moderate CYP3A4 inhibitor (eg, diltiazem), patients with an estimated glomerular filtration rate of less than 30 mL/min per 1·73m², and those with an estimated bodyweight of less than 70 kg. The primary outcome was 28-day mortality, secondary endpoints included time to discharge, the proportion of patients discharged from hospital within 28 days, and, in patients not on invasive mechanical ventilation at randomisation, a composite endpoint of invasive mechanical ventilation or death. All analyses were by intention-to-treat. The trial is registered with ISRCTN, 50189673, and, NCT04381936. Lancet Respir Med 2021 Published Online October 18, 2021 S2213-2600(21)00435-5 *The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the appendix (pp 2–25). Correspondence to: Prof Peter W Horby and Prof Martin J Landray, RECOVERY Central Coordinating Office, Oxford OX3 7LF, United Kingdom. See Online for appendix Findings Between Nov 27, 2020, and March 4, 2021, 11 340 (58%) of 19 423 patients enrolled into the RECOVERY trial were eligible to receive colchicine; 5610 (49%) patients were randomly assigned to the colchicine group and 5730 (51%) to the usual care group. Overall, 1173 (21%) patients in the colchicine group and 1190 (21%) patients in the usual care group died within 28 days (rate ratio 1·01 [95% CI 0·93 to 1·10]; p=0·77). Consistent results were seen in all prespecified subgroups of patients. Median time to discharge alive (10 days [IQR 5 to >28]) was the same in both groups, and there was no significant difference in the proportion of patients discharged from hospital alive within 28 days (3901 [70%] patients in the colchicine group and 4032 [70%] usual care group; rate ratio 0·98 [95% CI 0·94 to 1·03]; p=0·44). In those not on invasive mechanical ventilation at baseline,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop